Is Boston Scientific Stock a Buy?
There's a lot to appreciate about Boston Scientific Corporation (NYSE: BSX) from a healthcare investor's point of view. Beyond the company's massive line of specialist tools for healthcare workers, its stable of implantable medical devices like pacemakers, and a bevy of simple-yet-critical healthcare staples like catheters, Boston Scientific is effective at serving multiple high-value portions of the healthcare value chain. And, with leadership reporting a new emphasis on expanding the company's offerings in high-growth markets like prostate health and therapeutic oncology, future growth appears to be on track.
But Boston Scientific has a potential debt problem on the horizon, as its $10.6 billion in debt far eclipses its cash on hand of $370 million and rivals the size of its trailing-12-month revenue of $10.8 billion. Should wise investors buy Boston Scientific in hopes that its powerful core business will drive stock growth, or do the company's debts make it too dangerous to touch?
Image source: Getty Images.
Source Fool.com
